Twist Bioscience (NASDAQ:TWST) Price Target Lowered to $55.00 at Barclays

Twist Bioscience (NASDAQ:TWST) had its price objective lowered by Barclays from $60.00 to $55.00 in a report published on Monday, Benzinga reports. The brokerage currently has an overweight rating on the stock.

A number of other research analysts have also recently issued reports on TWST. TD Cowen lifted their price objective on shares of Twist Bioscience from $55.00 to $65.00 and gave the company a buy rating in a research note on Thursday, June 13th. Evercore ISI boosted their price target on Twist Bioscience from $46.00 to $50.00 and gave the stock an outperform rating in a report on Friday, May 3rd. Guggenheim began coverage on Twist Bioscience in a research note on Tuesday, June 4th. They issued a buy rating and a $53.00 price objective on the stock. Scotiabank lifted their target price on Twist Bioscience from $43.00 to $48.00 and gave the company a sector outperform rating in a research report on Monday, May 6th. Finally, Robert W. Baird increased their target price on shares of Twist Bioscience from $40.00 to $46.00 and gave the stock an outperform rating in a report on Monday. One investment analyst has rated the stock with a sell rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat, Twist Bioscience currently has an average rating of Moderate Buy and a consensus target price of $48.22.

Twist Bioscience Stock Up 2.0 %

Shares of NASDAQ:TWST traded up $0.91 during trading on Monday, reaching $46.24. 975,062 shares of the company traded hands, compared to its average volume of 1,051,731. The firm has a market capitalization of $2.69 billion, a PE ratio of -14.08 and a beta of 1.80. Twist Bioscience has a 52 week low of $14.42 and a 52 week high of $60.90. The company’s 50 day moving average is $50.58 and its two-hundred day moving average is $41.41.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings results on Friday, August 2nd. The company reported ($1.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.71). The company had revenue of $81.50 million during the quarter, compared to analyst estimates of $77.40 million. Twist Bioscience had a negative net margin of 69.24% and a negative return on equity of 31.61%. The firm’s revenue for the quarter was up 27.7% compared to the same quarter last year. During the same period last year, the firm earned ($1.01) EPS. As a group, research analysts anticipate that Twist Bioscience will post -3.08 EPS for the current year.

Insider Transactions at Twist Bioscience

In other Twist Bioscience news, SVP Paula Green sold 918 shares of the company’s stock in a transaction that occurred on Thursday, June 6th. The shares were sold at an average price of $51.33, for a total value of $47,120.94. Following the completion of the transaction, the senior vice president now directly owns 90,593 shares in the company, valued at approximately $4,650,138.69. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. In other news, CFO Adam Laponis sold 842 shares of the firm’s stock in a transaction dated Tuesday, July 9th. The stock was sold at an average price of $48.91, for a total transaction of $41,182.22. Following the completion of the transaction, the chief financial officer now directly owns 73,602 shares in the company, valued at $3,599,873.82. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, SVP Paula Green sold 918 shares of Twist Bioscience stock in a transaction that occurred on Thursday, June 6th. The stock was sold at an average price of $51.33, for a total value of $47,120.94. Following the completion of the transaction, the senior vice president now directly owns 90,593 shares in the company, valued at $4,650,138.69. The disclosure for this sale can be found here. Over the last three months, insiders have sold 11,289 shares of company stock worth $577,943. Insiders own 3.92% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. International Assets Investment Management LLC increased its position in shares of Twist Bioscience by 3,519.8% during the fourth quarter. International Assets Investment Management LLC now owns 4,018 shares of the company’s stock worth $148,000 after buying an additional 3,907 shares during the period. Sumitomo Mitsui Trust Holdings Inc. grew its holdings in Twist Bioscience by 2.9% during the 4th quarter. Sumitomo Mitsui Trust Holdings Inc. now owns 3,583,443 shares of the company’s stock worth $132,086,000 after acquiring an additional 99,511 shares during the period. Knights of Columbus Asset Advisors LLC acquired a new stake in Twist Bioscience during the 4th quarter worth about $2,296,000. New York State Common Retirement Fund raised its position in shares of Twist Bioscience by 5.0% in the 4th quarter. New York State Common Retirement Fund now owns 370,849 shares of the company’s stock worth $13,669,000 after acquiring an additional 17,715 shares in the last quarter. Finally, Victory Capital Management Inc. acquired a new position in shares of Twist Bioscience in the 4th quarter valued at about $274,000.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.